DANBURY, Conn., Sept. 10 /PRNewswire/ -- MannKind Corporation cordially invites the press to attend a ceremony on Wednesday, September 17, in Danbury, Conn., to mark completion of its new facility for production of the Technosphere(R) Insulin System. Start time is 10:45 am and the main ceremony will end at approximately 12 noon, with tours of the new facility to follow.
The events in Danbury are scheduled to include an announcement of the proposed marketing trade name for the company’s Technosphere(R) Insulin System, as well as a ribbon cutting, luncheon, and tours. Investors, medical and industry professionals, scientists, and employees, and local, state, and federal government officials have been invited and are expected to attend.
In the Technosphere(R) Insulin System, insulin molecules are loaded onto the company’s proprietary Technosphere(R) particles. These loaded particles are then aerosolized and inhaled as a dry powder into the deep lung using the company’s proprietary inhaler. Because of its rapid absorption into the bloodstream, Technosphere(R) Insulin has the potential to become the preferred means for controlling mealtime glucose excursions, the company believes.
Only guests with invitations and journalists with valid credentials who have preregistered will be admitted to the Danbury site. To preregister as a journalist, please contact Bill Kelly by phone or e-mail as indicated below.
For directions to the Danbury site at One Casper Street, visit http://harveymalis.com/mannkind. A press kit related to the event will be available from that link beginning September 17.
Interviews with MannKind executives can also be arranged by journalists who preregister.
CONTACT: Bill Kelly of HarveyMalis Communications LLC, +1-203-375-2696,
bill@harveymalis.com, for MannKind Corporation
Web site: http://harveymalis.com/mannkind/
